Carbon ion therapy for esophageal cancer is used in Japan as a non-surgical option for stage I disease. In a phase I/II trial at QST Hospital (Chiba), 30 patients with stage I esophageal cancer received carbon ion radiotherapy alone in 12 sessions over 3 weeks; 83% had a complete response and 5-year overall survival was 80.0% (IJROBP, 2023). This guide covers eligible stages, preoperative results, the schedule, costs for overseas patients and the documents to prepare. To find out whether your case can be reviewed, please use our esophageal cancer carbon ion therapy consultation.
Why use carbon ion therapy for esophageal cancer?
The esophagus runs through the middle of the chest, with the heart in front, the lungs on both sides and the spinal cord behind. Conventional X-ray radiotherapy deposits dose along its whole path, so late heart and lung effects years after esophageal cancer treatment have long been a concern.
Carbon ions release most of their energy at a set depth and then stop (the Bragg peak). Researchers at Kanagawa Cancer Center re-planned treatment for 15 patients with stage I esophageal cancer using three techniques (In Vivo, 2021). Mean heart dose was 9.6 Gy (RBE) with carbon ions versus 29.1 Gy with 3D conformal X-rays and 22.3 Gy with VMAT. Mean lung dose was 1.8 Gy (RBE) versus 5.3 Gy and 11.4 Gy. Maximum doses to the spinal cord and skin were also lowest with carbon ions.
The schedule is also short. Standard chemoradiotherapy takes around 6 weeks, while carbon ion therapy for stage I esophageal cancer is completed in 12 sessions over 3 weeks without chemotherapy. QST Hospital notes that it may suit older patients or those with other illnesses who cannot tolerate chemotherapy or surgery. See What is carbon ion therapy? for the basics.
Which stages are eligible?
QST Hospital lists clinical stage I primary esophageal cancer as an indication: the tumor extends no deeper than the submucosa, with no spread to lymph nodes or other organs, regardless of histological type. The Japanese Society for Radiation Oncology (JASTRO) treatment policy of July 2022 also includes short-course preoperative irradiation for stage II and III disease.
| Stage / situation | Approach | Dose / sessions | Basis |
|---|---|---|---|
| Stage I (up to submucosa, node-negative) | Carbon ions alone, no chemotherapy | 48.0–50.4 Gy (RBE), 12 sessions, about 3 weeks | QST Hospital, JASTRO policy (2022) |
| Stage II–III (surgery planned) | Preoperative carbon ions, then surgery | 33.6–38.4 Gy (RBE), 8 sessions | JASTRO policy (2022), phase I/II trial |
| Single lymph node recurrence after surgery | Salvage irradiation of the node | 48.0 Gy (RBE), 12 sessions, 3 weeks | QST Hospital retrospective analysis (2018) |
Carbon ion therapy is generally not recommended when there are metastases in several organs, deep invasion of the trachea or aorta, or a fistula in the esophagus. The final decision is made by the Japanese team after reviewing imaging and endoscopy. General criteria are in Carbon ion therapy eligibility.
Stage I clinical trial results
The key evidence is a phase I/II trial by QST Hospital and Chiba University published in IJROBP in 2023. Thirty patients with clinical stage I (T1bN0M0) esophageal squamous cell carcinoma received carbon ions alone in 12 sessions over 3 weeks. The dose was escalated from 43.2 to 50.4 Gy (RBE), which established today's range of 48–50.4 Gy (RBE). Median follow-up was 86.7 months.
| Outcome | Result |
|---|---|
| Complete response | 25 of 30 (83%) |
| 5-year overall survival | 80.0% |
| 5-year local control | 69.3% |
| 5-year disease-free survival | 62.6% |
| Grade 3 acute effects | Esophagitis 2, neutropenia 1, lymphopenia 1 |
The authors concluded that short-course carbon ion therapy is a minimally invasive and effective treatment. An earlier QST analysis of 16 patients treated through 2012 showed 3-year overall survival of 100% and 4-year survival of 83%. Four of the 16 had a local recurrence, and all received focal salvage treatment safely. No late effects of grade 3 or higher were seen, and none of the heart or lung complications typical of chemoradiotherapy were reported.
Further treatment remains possible after recurrence. In 2022, Gunma University and QST Hospital reported a patient whose new esophageal lesion, found six years after carbon ion therapy, was removed safely by thoracoscopic surgery; she went home on day 17 without complications.
Preoperative and lymph node recurrence results
For stage II and III disease, carbon ions have been studied before surgery to shrink the tumor. In a phase I/II trial by Chiba University and QST (Journal of Surgical Oncology, 2012), 31 patients with thoracic esophageal squamous cell carcinoma received 8 sessions before surgery 4 to 8 weeks later. No cancer cells remained in the removed tissue (pathological complete response) in 12 of 31 (38.7%). Stage II patients had 3-year survival of 85% and 5-year survival of 77%. Acute toxicity occurred in only 1 patient (3.2%), with no late toxicity, and no one missed surgery because of side effects.
A single lymph node recurrence after surgery can also be reviewed. QST Hospital treated 10 such patients with 48 Gy (RBE) in 12 sessions; local control of the treated nodes was 92.4% at 2, 3 and 5 years, with no grade 3 or higher toxicity (Anticancer Research, 2018). Four had previously received radiotherapy to the same area. See Carbon ion re-irradiation after radiotherapy.
Schedule and cost
Stage I treatment is given 4 days a week, 12 sessions over about 3 weeks. Overseas patients first have a records review, an initial visit, immobilization device fitting and a planning CT, followed by 1 to 2 weeks before treatment starts. QST Hospital says patients may return home in this period if they are back by the day before treatment begins. See Carbon ion therapy treatment period.
| Cost item | Amount (QST Hospital) | Note |
|---|---|---|
| Carbon ion therapy (self-pay) | JPY 5.786 million (tax incl.) | Overseas patients without Japanese public insurance |
| Hospital stay, visits, tests | JPY 33 per medical fee point (tax incl.) | Charged for services actually used |
| Medical coordinator fee | Not included | Varies by registered coordinator or agency |
| Accommodation, flights, interpreting | Not included | Plan for a stay of about 4 to 5 weeks |
Amounts are from QST Hospital's overseas patient page, checked on 27 October 2026. Fees and procedures differ between Japanese centers; compare them in Carbon ion therapy cost and Japanese carbon ion centers.
Cost and schedule depend on stage, admission and extra tests. Send us your current records via our contact page or call +82-2-517-5117, and we will explain which hospitals can review your case and how to prepare.
Documents to prepare
Endoscopy findings are especially important for staging esophageal cancer. These records speed up review by Japanese hospitals:
- Referral letter: diagnosis, stage and previous treatment (surgery, chemotherapy, radiotherapy)
- Endoscopy report and images, and endoscopic ultrasound if available (to confirm depth up to the submucosa)
- Pathology report (squamous cell carcinoma or adenocarcinoma) and slides if needed
- Original CT and PET-CT images from the last 1 to 2 months (DICOM on CD)
- Blood tests, other conditions such as heart or lung disease, and a medication list
See Carbon ion therapy documents checklist and our summary of QST material in Esophageal cancer carbon ion therapy.
FAQ
Can carbon ion therapy replace surgery for esophageal cancer?
For stage I disease, carbon ions alone can be chosen instead of surgery. The QST phase I/II trial reported 5-year overall survival of 80.0%. If surgery is possible, surgery, endoscopic resection and carbon ion therapy are compared with your doctors.
Is chemotherapy needed at the same time?
No. Stage I treatment uses carbon ions alone, which is why it is also considered for older patients who cannot tolerate chemotherapy.
Can I eat during treatment?
Most patients eat normally. Painful swallowing from esophagitis may appear late in treatment and is managed with soft food and pain relief. Grade 3 esophagitis occurred in 2 of 30 trial patients. See Carbon ion therapy side effects.
Can stage II or III be treated?
Preoperative irradiation has been studied for stage II and III, with 5-year survival of 77% reported for stage II. It is planned together with surgery, so a Japanese team must review the case.
How much does it cost for overseas patients?
QST Hospital lists JPY 5.786 million (tax included) for carbon ion therapy for patients without Japanese public insurance. Hospital stay and tests are charged separately at JPY 33 per medical fee point.
Related articles
Wondering if carbon ion therapy is possible for you, and what it costs?
We help you prepare consultations with Japanese institutions and provide medical interpreting.
Free consultationCall +82-2-517-5117Sources
- Isozaki T, et al. A Phase I/II Trial of Definitive Carbon Ion Radiotherapy for Clinical T1bN0M0 Esophageal Squamous Cell Carcinoma. Int J Radiat Oncol Biol Phys 2023;117(2):416-421
- QST Hospital — Esophageal cancer (indications for carbon ion radiotherapy)
- Akutsu Y, et al. Phase I/II trial of preoperative short-course carbon-ion radiotherapy for esophageal squamous cell carcinoma. J Surg Oncol 2012;105(8):750-755
- Isozaki Y, et al. Salvage carbon-ion radiotherapy for isolated lymph node recurrence following curative resection of esophageal cancer. Anticancer Res 2018;38(11):6453-6458
- Takakusagi Y, et al. Dosimetric comparison between carbon-ion radiotherapy and photon radiotherapy for stage I esophageal cancer. In Vivo 2021;35(1):447-452
- Kuriyama K, et al. Salvage thoracoscopic esophagectomy after carbon-ion radiotherapy. Surg Case Rep 2022;8:25
- JASTRO particle beam therapy treatment policy: esophageal cancer (2022, Japanese document)
- QST Hospital — For patients from abroad (procedure and fees)
General information based on public sources; not a substitute for diagnosis or treatment. Eligibility is decided by the treating physicians. Written by the FTH editorial team.